The development of immune checkpoint inhibitors [monoclonal antibodies targeting
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD …

The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval
of newer agent like atezolimumab for use in patients with advanced stage urothelial …

Objective To report the clinicopathologic features and outcome of myositis in patients treated
with immune checkpoint inhibitors (ICIs)(irMyositis). Methods We retrospectively analyzed …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Objective: To report the clinical features of myasthenia gravis (MG) induced by treatment
with immune checkpoint inhibitors using 2-year safety databases based on postmarketing …

Objectives To evaluate the prevalence and type of rheumatic immune-related adverse
events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the …

Aim To characterise clinical presentation, laboratory and histopathologic characteristics and
assess the treatment and outcome of neuromuscular side-effects of checkpoint therapy …

ICI-associated irAEs constitute a new group of neurologic complications of systemic
anticancer therapies. Although potentially severe, these rare neurologic toxicities are often …

Background Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-
1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) …

Objective To estimate the incidence of immune checkpoint inhibitor–related myositis (ICI‐
myositis) in cancer patients receiving ICIs, and to report associated clinical manifestations …